Chao-Hui Dong1, Zhang-Min Wang1, Si-Yu Chen2. 1. Department of Cardio-Pulmonary Rehabilitation, The Affiliated Rehabilitation Hospital of Chongqing Medical University, China. 2. Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: freecqmu@126.com.
Abstract
OBJECTIVES: Neutrophil to lymphocyte ratio (NLR) might be associated with the mortality or major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients. We performed a meta-analysis to evaluate the correlation between NLR and mortality/MACEs in ACS. METHODS: We assessed clinical trials through Pubmed, EMBASE, the Cochrane Library and Web of science in investigating the association between NLR and mortality/MACEs in ACS patients up to August 15, 2017. The primary outcome was mortality or recurrent MACEs. RESULTS: In total, 8 studies of 9406 patients were included in the systematic and meta-analysis. Our analysis indicated that elevated pretreatment NLR was a poor prognostic marker for patients with recent ACS in predicting medium to long-term mortality/MACEs (OR 1.26, 95%CI 1.13-1.41). And the analysis indicated that higher pretreatment NLR value was associated with higher in-hospital mortality in ACS patients (OR 6.39, 95%CI 1.49-27.38, p<0.001). The NLR value of 5.0 maybe a cut-off value for ACS risk. CONCLUSIONS: In patients with a recent ACS, an elevated pretreatment NLR value is effective in predicting the risk of mortality/MACEs.
OBJECTIVES: Neutrophil to lymphocyte ratio (NLR) might be associated with the mortality or major adverse cardiac events (MACEs) in acute coronary syndrome (ACS) patients. We performed a meta-analysis to evaluate the correlation between NLR and mortality/MACEs in ACS. METHODS: We assessed clinical trials through Pubmed, EMBASE, the Cochrane Library and Web of science in investigating the association between NLR and mortality/MACEs in ACS patients up to August 15, 2017. The primary outcome was mortality or recurrent MACEs. RESULTS: In total, 8 studies of 9406 patients were included in the systematic and meta-analysis. Our analysis indicated that elevated pretreatment NLR was a poor prognostic marker for patients with recent ACS in predicting medium to long-term mortality/MACEs (OR 1.26, 95%CI 1.13-1.41). And the analysis indicated that higher pretreatment NLR value was associated with higher in-hospital mortality in ACS patients (OR 6.39, 95%CI 1.49-27.38, p<0.001). The NLR value of 5.0 maybe a cut-off value for ACS risk. CONCLUSIONS: In patients with a recent ACS, an elevated pretreatment NLR value is effective in predicting the risk of mortality/MACEs.
Authors: Artur Nóbrega Lima Rodrigues de Morais; Victor Matheus Ribeiro Baylão; Tamires Martins Silva; Alexandra Gomes Dos Santos; Mayara Azevedo; Adilson J M de Oliveira Journal: Neurosurg Rev Date: 2021-02-15 Impact factor: 3.042
Authors: Samantha E Halpern; Dimitrios Moris; Brian I Shaw; Madison K Krischak; Danae G Olaso; Samuel J Kesseli; Kadiyala Ravindra; Lisa M McElroy; Andrew S Barbas Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Murat Sargın; Müge Taşdemir Mete; Sevinç Bayer Erdoğan; Hüseyin Kuplay; Murat Baştopçu; Fatih Bayraktar; Murat Acarel; Serap Aykut Aka Journal: Turk Gogus Kalp Damar Cerrahisi Derg Date: 2019-06-21 Impact factor: 0.332